

## Press Release

12 April 2023 13:00:00 CEST

# 2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.

2cureX announced today that it has been awarded a grant of 1.5 M DKK to support the development of IndiTreat® Neo, a test to support therapy decision-making in neo-adjuvant treatment of non-metastatic colorectal cancer.

### Acceleration of IndiTreat® portfolio expansion to early stages of colorectal cancer

In the last years, 2cureX has successfully introduced three CE-IVD marked IndiTreat® tests for metastatic colorectal cancer (mCRC) into the European market. This new grant will support the expansion to earlier, non-metastatic stages of colorectal cancer (CRC).

Almost all patients in stages II and III undergo surgery of their colorectal tumor. Chemotherapy treatment prior to surgery (neoadjuvant) led to significant tumor reduction and prolonged disease-free-survival in a large, international randomized trial (FOXTROT) including more than 1500 patients and is on the way to becoming standard-of-care. With the support from the Innovation Fund Denmark, IndiTreat® will be used for selecting the most efficacious neoadjuvant chemotherapy treatment in a new series of trials. Success in these neoadjuvant trials will pave the way for introduction of a new IndiTreat® Neo product and change of international guidelines for treatment of CRC.

Ole Thastrup, CSO and Founder of 2cureX says “Clinical validation of an IndiTreat® Neo test will provide the basis for an exciting expansion of the IndiTreat® product portfolio to include tests for both metastatic and non-metastatic disease stages. This will not only dramatically increase the number of eligible patients, but also show the broad applicability of the IndiTreat® technology”, Ole Thastrup continues: “A clear medical need for an IndiTreat® Neo test has been confirmed by a large number of hospitals covered through our distribution network”.

For more information about 2cureX:

---

Fernando Andreu, Chief Executive Officer

E-mail: [fa@2curex.com](mailto:fa@2curex.com)

Telephone: +45 2279 5399

[www.2curex.com](http://www.2curex.com)

Ole Thastrup, Chief Science Officer

E-mail: [ot@2curex.com](mailto:ot@2curex.com)

Telephone: +45 2211 5399

[www.2curex.com](http://www.2curex.com)

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.com](http://www.2cureX.com)

Certified Adviser: Redeye AB, +46 8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)

*This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-12 13:00 CEST.*

## Attachments

---

[2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.](#)